Instrument Inactif

Gouvernance Intercept Pharmaceuticals, Inc.

ICPT

US45845P1084

Recherche biotechnologique et médicale

Comité Exécutif: Intercept Pharmaceuticals, Inc.

Dirigeant

Fonctions occupéesDepuis

Rocco Venezia

51 ans

Director of Finance/CFO

01/11/2023

Jose Truzman

General Counsel

01/11/2023

Vivek Devaraj

President

Deryk David

Sales & Marketing

Victoria Carey

Sales & Marketing

Richard Johnson

Human Resources Officer

01/01/2017

Sangeeta Sawhney

Chief Tech/Sci/R&D Officer

01/04/2024

Veruska di Sena

Chief Tech/Sci/R&D Officer

01/09/2024

Composition du Conseil d'Administration: Intercept Pharmaceuticals, Inc.

Administrateur

ComitésDepuis

Vivek Devaraj

Chairman

Dernières Nominations: Intercept Pharmaceuticals, Inc.

23/10/23	Persephone Biosciences nomme Daniel Bradbury président du conseil d'administration	CI
26/07/22	Intercept Pharmaceuticals, Inc. annonce la démission de Bryan Ball en tant que directeur de la qualité et vice-président principal des opérations, à compter du 12 août 2022	CI
02/06/22	Intercept Pharmaceuticals, Inc. annonce la démission de Gail Cawkwell en tant que vice-présidente principale, Affaires médicales, sécurité et pharmacovigilance	CI
10/01/22	Intercept Pharmaceuticals, Inc. annonce la démission de Lisa M. DeFrancesco en tant que Senior Vice President, Investor Relations & Corporate Affairs, à compter du 28 janvier 2022.	CI

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Intercept Pharmaceuticals, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Andrew Saik

Director of Finance/CFO

21/06/2021

01/06/2024

Linda Richardson

Corporate Officer/Principal

01/01/2018

01/01/2024

David Ford

Human Resources Officer

01/05/2017

01/12/2023

Mark Pruzanski

Director/Board Member	04/09/2002	08/11/2023
Chief Executive Officer	04/09/2002	01/01/2021
Founder	04/09/2002	08/11/2023
President	04/09/2002	01/01/2021

Srini Akkaraju Akkaraju

Director/Board Member	01/10/2012	08/11/2023
Independent Dir/Board Member	01/10/2012	08/11/2023

Francesco Balestrieri

Director/Board Member

08/11/2023

Dagmar Rosa-Bjorkeson

Director/Board Member	01/04/2021	08/11/2023
Independent Dir/Board Member	01/04/2021	08/11/2023

Nancy Miller-Rich

Director/Board Member	24/04/2018	08/11/2023
Independent Dir/Board Member	24/04/2018	08/11/2023

Keith Gottesdiener

Director/Board Member	01/07/2016	08/11/2023
Independent Dir/Board Member	01/07/2016	08/11/2023

Jerome Durso

Director/Board Member	01/01/2021	08/11/2023
Chief Executive Officer	01/01/2021	08/11/2023
Chief Operating Officer	23/02/2017	01/01/2021
President	01/01/2021	08/11/2023

Gino Santini

Director/Board Member	01/11/2015	08/11/2023
Independent Dir/Board Member	01/11/2015	08/11/2023

Luca Benatti

Director/Board Member	17/07/2014	08/11/2023
Independent Dir/Board Member	17/07/2014	08/11/2023

Glenn Sblendorio

Director/Board Member	17/02/2014	08/11/2023
Independent Dir/Board Member	17/02/2014	08/11/2023

Daniel Bradbury

Director/Board Member	01/07/2016	08/11/2023
Independent Dir/Board Member	01/07/2016	08/11/2023

Stefano Pasi

Director/Board Member

08/11/2023

Paolo Fundarò

Director/Board Member	01/01/2006	01/10/2015
Chairman	01/10/2015	08/11/2023
Independent Dir/Board Member	01/01/2006	08/11/2023

Bryan Ball

Chief Operating Officer	-	01/08/2022
Corporate Officer/Principal	01/01/2021	-

Gail Cawkwell

Chief Tech/Sci/R&D Officer

01/02/2018

01/06/2022

Lisa DeFrancesco

Investor Relations Contact

09/09/2019

28/01/2022

Christopher Frates

Public Communications Contact

01/11/2021

Caileigh Dougherty

Public Communications Contact

01/08/2021

M. Berrey

Chief Tech/Sci/R&D Officer

09/06/2021

Daniel Welch

Director/Board Member	01/11/2015	27/05/2021
Independent Dir/Board Member	01/11/2015	27/05/2021

Sandipkumar S. Kapadia

Director of Finance/CFO	01/07/2016	26/03/2021
Treasurer	01/07/2016	26/03/2021

Jason Campagna

Chief Tech/Sci/R&D Officer

01/12/2019

05/03/2021

Richard Kim

Corporate Officer/Principal

01/07/2015

15/02/2021

Jared M. Freedberg

General Counsel	11/01/2021	-
Corporate Secretary	11/01/2021	-

Ingrid Delaet

General Counsel

01/01/2016

01/01/2021

Lisa Bright

Corporate Officer/Principal

17/11/2014

01/01/2021

Ryan Sullivan

General Counsel	01/02/2018	11/12/2020
Corporate Secretary	01/02/2018	11/12/2020

Daniel Hood

General Counsel

01/08/2015

01/07/2020

Leah Neufeld

Human Resources Officer

01/08/2015

01/09/2019

Mark Vignola

Investor Relations Contact	01/06/2015	01/05/2019
Corporate Officer/Principal	01/01/2018	01/05/2019

David Shapiro

Chief Tech/Sci/R&D Officer

01/04/2007

01/05/2019

Melissa Rewolinski

Corporate Officer/Principal

01/04/2008

01/07/2018

Rachel McMinn

Corporate Officer/Principal

30/04/2014

01/12/2017

Christian Weyer

Chief Tech/Sci/R&D Officer

27/11/2017

Bryan Yoon

General Counsel	01/01/2013	01/11/2017
Corporate Secretary	01/01/2013	01/11/2017

Joseph Vazzano

Corporate Officer/Principal

01/01/2016

01/07/2017

Senthil Sundaram

Corporate Officer/Principal

01/02/2013

01/03/2017

Jonathan Silverstein

Director/Board Member	01/10/2015	19/07/2016
Chairman	23/10/2013	01/10/2015
Independent Dir/Board Member	01/01/2009	19/07/2016

Klaus Veitinger

Director/Board Member	09/08/2012	01/07/2016
Independent Dir/Board Member	09/08/2012	01/07/2016

Barbara Duncan

Director of Finance/CFO	01/05/2009	01/06/2016
Corporate Secretary	01/05/2009	01/06/2016
Treasurer	01/01/2010	01/06/2016

Nicole S. Williams

Director/Board Member	10/07/2009	24/11/2015
Independent Dir/Board Member	01/01/2008	24/11/2015

Sanj Patel

Director/Board Member	17/02/2014	24/11/2015
Independent Dir/Board Member	17/02/2014	24/11/2015

Juan Carlos Lopez-Talavera

Corporate Officer/Principal

22/06/2015

Daniel Paul Regan

Corporate Officer/Principal

04/03/2013

01/02/2015

Lorenzo M. Tallarigo

Director/Board Member	18/10/2013	17/07/2014
Chairman	01/01/2008	18/10/2013
Independent Dir/Board Member	01/01/2008	17/07/2014

Paul Sekhri

Director/Board Member

05/08/2009

01/09/2012

Barry Greene

Director/Board Member

08/02/2011

09/08/2012

Kenneth Noonan

Director/Board Member

09/08/2012

Robert More

Chairman

01/08/2012

Robert P. Roche

Director/Board Member

05/05/2009

01/01/2011

Alex Martin Martin

Chief Operating Officer

01/01/2007

Pia Lindström

General Counsel

05/08/2009

Luciano Adorini

Chief Tech/Sci/R&D Officer

01/01/2008

Roberto Pellicciari

Founder	04/09/2002	-
Corporate Officer/Principal	28/09/2009	-

Chau Khuong

Director/Board Member

Deepa Rajagopalan

Corporate Officer/Principal

Drew Cronin-Fine

Corporate Officer/Principal

Andrew Saich

Corporate Officer/Principal

Justine O'Malley

Corporate Officer/Principal

Mary J. Grendell

General Counsel	-	-
Corporate Secretary	-	-

Peter Morgan Kash

Director/Board Member

27/11/2009

James Mervis

Chairman

Kristin Gustafson

Human Resources Officer

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	7
Femme	1

Dont comité exécutif

Homme	7
Femme	1

Dont Administrateurs

Homme	1
Femme	0

Révisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Intercept Pharmaceuticals, Inc. est une société biopharmaceutique qui se concentre sur le développement et la commercialisation de produits thérapeutiques pour traiter les maladies hépatiques progressives non virales dont les besoins médicaux ne sont pas satisfaits, en utilisant sa chimie des acides biliaires. Ses produits candidats comprennent Ocaliva (obeticholic (OCA)) pour la fibrose du foie due à la stéatohépatite non alcoolique (NASH), OCA et Bezafibrate, et d'autres produits candidats. Le produit commercialisé par la société, Ocaliva, est un agoniste du récepteur farnésoïde X (FXR) pour le traitement de la cholangite biliaire primitive (CBP) en association avec l'acide ursodésoxycholique (UDCA) chez les adultes ayant une réponse inadéquate à l'UDCA ou en monothérapie chez les adultes ne pouvant pas tolérer l'UDCA. La société évalue la tolérabilité de l'OCA en association avec le bézafibrate chez les patients atteints de CBP dans le cadre d'une étude de phase II en dehors des États-Unis. Ses autres composés en sont aux premiers stades de la recherche et du développement, notamment le composé INT-787, un agoniste du FXR, qui fait l'objet d'un essai clinique de phase IIa.

Employés

341

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société